Oncimmune Holdings (UK) Performance
| ONC Stock | 1.14 0.05 4.20% |
The company holds a Beta of -1.4, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Oncimmune Holdings are expected to decrease by larger amounts. On the other hand, during market turmoil, Oncimmune Holdings is expected to outperform it. At this point, Oncimmune Holdings plc has a negative expected return of -3.57%. Please make sure to check Oncimmune Holdings' standard deviation, maximum drawdown, kurtosis, as well as the relationship between the total risk alpha and potential upside , to decide if Oncimmune Holdings plc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Oncimmune Holdings plc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 3.2 M | |
| Free Cash Flow | -3.4 M |
Oncimmune |
Oncimmune Holdings Relative Risk vs. Return Landscape
If you would invest 1,580 in Oncimmune Holdings plc on December 18, 2024 and sell it today you would lose (1,466) from holding Oncimmune Holdings plc or give up 92.78% of portfolio value over 90 days. Oncimmune Holdings plc is generating negative expected returns and assumes 10.6771% volatility on return distribution over the 90 days horizon. Simply put, 95% of stocks are less volatile than Oncimmune, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Oncimmune Holdings Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncimmune Holdings' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncimmune Holdings plc, and traders can use it to determine the average amount a Oncimmune Holdings' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3343
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ONC |
Estimated Market Risk
| 10.68 actual daily | 95 95% of assets are less volatile |
Expected Return
| -3.57 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.33 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Oncimmune Holdings is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncimmune Holdings by adding Oncimmune Holdings to a well-diversified portfolio.
Oncimmune Holdings Fundamentals Growth
Oncimmune Stock prices reflect investors' perceptions of the future prospects and financial health of Oncimmune Holdings, and Oncimmune Holdings fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncimmune Stock performance.
| Return On Equity | -7.61 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (1.32) % | ||||
| Operating Margin | (1.18) % | ||||
| Current Valuation | 5.55 M | ||||
| Shares Outstanding | 111.77 M | ||||
| Price To Book | 49.27 X | ||||
| Price To Sales | 0.49 X | ||||
| Revenue | 2.74 M | ||||
| EBITDA | (3 M) | ||||
| Total Debt | 5.12 M | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (3.38 M) | ||||
| Earnings Per Share | (0.05) X | ||||
| Total Asset | 4.9 M | ||||
| Retained Earnings | (46.78 M) | ||||
About Oncimmune Holdings Performance
By analyzing Oncimmune Holdings' fundamental ratios, stakeholders can gain valuable insights into Oncimmune Holdings' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oncimmune Holdings has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncimmune Holdings has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Oncimmune Holdings plc performance evaluation
Checking the ongoing alerts about Oncimmune Holdings for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncimmune Holdings plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncimmune Holdings generated a negative expected return over the last 90 days | |
| Oncimmune Holdings has high historical volatility and very poor performance | |
| Oncimmune Holdings may become a speculative penny stock | |
| Oncimmune Holdings has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 2.74 M. Net Loss for the year was (4.11 M) with profit before overhead, payroll, taxes, and interest of 1.23 M. | |
| Oncimmune Holdings generates negative cash flow from operations | |
| About 32.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Oncimmune Holdings' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncimmune Holdings' stock is overvalued or undervalued compared to its peers.
- Examining Oncimmune Holdings' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncimmune Holdings' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncimmune Holdings' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncimmune Holdings' stock. These opinions can provide insight into Oncimmune Holdings' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Oncimmune Stock analysis
When running Oncimmune Holdings' price analysis, check to measure Oncimmune Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncimmune Holdings is operating at the current time. Most of Oncimmune Holdings' value examination focuses on studying past and present price action to predict the probability of Oncimmune Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncimmune Holdings' price. Additionally, you may evaluate how the addition of Oncimmune Holdings to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| CEOs Directory Screen CEOs from public companies around the world |